886 results on '"Abraham, Ivo"'
Search Results
2. Optimizing Postpartum Care in Rural Communities: Insights from Women in Arizona and Implications for Policy
3. A Least Absolute Shrinkage and Selection Operator-Derived Predictive Model for Postoperative Respiratory Failure in a Heterogeneous Adult Elective Surgery Patient Population
4. A LASSO-DERIVED PREDICTIVE MODEL FOR POSTOPERATIVE RESPIRATORY FAILURE IN A HETEROGENEOUS ADULT ELECTIVE SURGERY PATIENT POPULATION
5. Outcomes and risk factors for delayed-onset postoperative respiratory failure: a multi-center case-control study by the University of California Critical Care Research Collaborative (UC3RC)
6. Manuka combinations with nigella sativa and hydroxyurea in treating iron overload of pediatric β-thalassemia major, randomized clinical trial
7. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
8. The role of cytokines and Indolamine-2.3 dioxygenase in experiencing a psycho-neurological symptom cluster in hematological cancer patients: IL-1alpha, IL-1beta, IL-4, IL-6, TNF-alpha, kynurenine, and tryptophan
9. Biomarkers of gut barrier dysfunction in obstructive sleep apnea: A systematic review and meta-analysis
10. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves.
11. Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.
12. Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia
13. Neuropsychological Effects of Chemotherapy: Systematic Review of Longitudinal Studies on Objective Cognitive Impairment in Breast Cancer Patients
14. Association of chemotherapy and subjective cognitive impairment in breast cancer patients: Meta-analysis of longitudinal prospective cohort studies
15. Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis
16. Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma
17. No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)
18. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
19. The economic burden of Ebola virus disease: a review and recommendations for analysis
20. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves
21. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)
22. Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience
23. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma
24. Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
25. Examining Risk of Heart Failures With Trastuzumab (Herceptin) Use Among Patients With HER2+ Breast Cancer Using Surveillance, Epidemiology, and End Results (Seer) Medicare: A Retrospective Cohort Study
26. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure
27. OSA and Neurocognitive Impairment in Children With Congenital Heart Disease
28. Extended Medicaid coverage will improve access but insufficient to enhance postpartum care utilization: a secondary analysis of the 2016–2019 Arizona Medicaid claims
29. What to expect in 2024: important health economics and outcomes research (HEOR) trends
30. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis
31. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis
32. Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization
33. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)
34. Polytomous Rasch Analyses of Surgeons' Decision-Making on Choice of Procedure in Endoscopic Lumbar Spinal Stenosis Decompression Surgeries.
35. What to expect in 2024: important health economics and outcomes research (HEOR) trends.
36. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma
37. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
38. Preparing for the third decade of biosimilars
39. Mental Health Outreach to Rural Elderly: Service Delivery to a Forgotten Risk Group
40. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review
41. Physicians’ perceptions, expectations, and experiences of clinical pharmacists in Jordan-2017
42. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study
43. Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
44. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI
45. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region
46. The Changing Environment in Postgraduate Education in Orthopedic Surgery and Neurosurgery and Its Impact on Technology-Driven Targeted Interventional and Surgical Pain Management: Perspectives from Europe, Latin America, Asia, and The United States
47. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey
48. “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis
49. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
50. Measurement of fatigue: Comparison of the reliability and validity of single-item and short measures to a comprehensive measure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.